Nuo Therapeutics, Inc. (AURX) stock

AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/30

$1.26−0.04 (-3.08%)

Close on Oct 19, 2026Market cap $60.99MP/E –Yield –

Nuo Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Nuo Therapeutics's EV/EBITDA was 498.8× on Jan 29, 2021.

Period	Period end	Value	Change (pts)
2021	Jan 29, 2021	498.8×	−65.2
2020	Dec 31, 2020	564.0×	–

Parsed from the XBRL in Nuo Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AURX.

Revenue growth166.6% · median 60.7%

Gross margin64.1% · median 63.2%

Operating margin-33.3% · median -321.7%

Net margin-38.7% · median -407.3%

Advertisement
300 × 250

See a number that looks wrong?